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ABSTRACT

ERYTHROCYTE-ASSOCIATED TRANSIENTS IN CAPILLARY PO2 IN
THE RAT SPINOTRAPEZIUS MUSCLE DURING HEMODILUTION
WITH HESPAN AND A HEMOGLOBIN-BASED OXYGEN CARRIER
By Matthew C. Barker
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University

Virginia Commonwealth University, 2005
Advisor: Roland N. Pittman, Ph.D.
Department of Physiology

Hemoglobin-based oxygen carriers for use as transfusion fluids have emerged as a
leading technology directed at stemming shortages of a safe blood supply and providing a
readily available resuscitation fluid in various trauma situations. The purpose of this
investigation was to determine the effects of isovolemic hernodilution with Hespan and a
hemoglobin-based oxygen carrier (HBOC) on erythrocyte-associated transients (EATs) in
capillary PO2. The particulate nature of blood flow in capillaries, when observed from a
stationary observation point, results in fluctuations of PO2 as alternating red blood cells
and plasma gaps move through the detection region. Therefore, through experimental
methods which provided the necessary temporal and spatial resolution required to make
such measurements, EATs can be observed and corresponding PO2 fluctuations can be
determined. The spinotrapezius muscle in sixteen Sprague-Dawley rats was exteriorized
for intravital microscopy measurements in capillaries. Capillary PO2 was measured using

Pd-porphyrin phosphorescence quenching microcopy. The hemodiluents used in
isovolemic hemodilution included Hespan, a non-oxygen carrying plasma expander, and
OxyglobinB, a HBOC. Two isovolemic hemodilution steps were performed, reducing the
systemic hematocrit to an average of 27.5% after the first step and 13.5% after the second
step. Results showed that erythrocyte-associated transients in PO2 can be observed in the
rat spinotrapezius with significant differences occurring between red blood cell and
plasma gap PO2 under control conditions, isovolemic hemodilution with Oxyglobin after
step one, and isovolemic hemodilution with Hespan after step two. This study concludes
that EATs are observable and POz transients relating to EATs can be measured in the rat
spinotrapezius muscle. Furthermore, it can be concluded that the HBOC Oxyglobin
caused a decrease in erythrocyte-associated capillary POz transients, as well as a general
decrease in capillary PO2. In addition, this study concludes that erythrocyte-associated
capillary PO2 transients can best be observed under control conditions and after step two
of isovolemic hemodilution with Hespan.

INTRODUCTION
The Blood and Circulation
Oxygen is a fundamental component required to sustain life of most cells in the
body of all mammals. The metabolic need for oxygen of cells in tissues requires the
transport of oxygen to those sites. Mammals appear to have evolved in accordance with
the principles of symmorphosis (i.e., a state of structural design corresponding to
functional needs resulting from regulated morphogenesis), possessing tissues, blood, and
a circulatory structure to carry out these essential functions of life (Weibel 1984).

Blood Composition
Circulating blood volume accounts for approximately 7% of body weight. About
55% of this volume is plasma and the other 45% is composed of blood cells. Dissolved
in the plasma is a complex solution of gases, salts, proteins, carbohydrates, and lipids
(Beme and Levy 1998). In the blood cell component there are approximately between
7,000 and 12,000 white cells, between 150,000 and 400,000 platelets, and between 4.5
and 5.5 million red blood cells in a volume of a cubic millimeter of blood (Nucci and
Abuchowski 1998). These two components perform multiple tasks including: the
transport of nutrients, oxygen, carbon dioxide and waste products; the delivery of
hormones, leukocytes, and platelets to their sites of action; and the distributions of water,
other solutes, and heat (Beme and Levy 1998; Nucci and Abuchowski 1998).

Red Blood Cells and Hemoglobin
Red blood cells, or erythrocytes, are nonnucleated, terminally differentiated cells
that possess an average lifetime of 120 days. They are flexible, biconcave disks with an
average diameter of 7 pm (Berne and Levy 1998). Erythrocytes are hollow vesicles filled
with molecules called hemoglobin that have the capacity to carry oxygen. Hemoglobin
turns such a hollow vesicle into a discrete oxygen transporting package, with hemoglobin

'

occupying approximately a quarter of each cell's internal volume (about 3 . 10.' glcell)
(Weibel 1984).
Hemoglobin (MW = 66,000 Da) is a protein tetramer with two a and two P
polypeptide chains. Each polypeptide chain has an iron-containing heme group which is
used to reversibly bind oxygen. Consequently, four molecules of oxygen can bind to
each hemoglobin molecule (Weibel 1984; Chang 1999).
As individual oxygen molecules bind to a subunit of the hemoglobin molecule, its
configuration is altered, allowing for increased binding affinity of each subsequent
oxygen molecule, until all four binding sites are occupied (i.e., positive cooperativity).
This cooperativity results in a sigmoidally shaped binding curve that can undergo shifts
influenced by local factors thereby affecting the oxygen affinity of hemoglobin. These
factors include PC02, pH, temperature, and 2,3-diphosphoglycerate (2,3-DPG)
concentration (Berne and Levy 1998; Costanzo 1998).
Oxygen is transported in the blood in two forms: 1) dissolved in the plasma and 2)
bound to hemoglobin. Dissolved oxygen comprises approximately 2% of the total
oxygen content of blood and is inadequate to supply the demands of the tissues. The

remaining 98% of the oxygen is reversibly bound to hemoglobin, so that the oxygen
content of blood is principally determined by the oxygen binding capacity and the
concentration of hemoglobin (Costanzo 1998).
In the lungs, there is a reciprocal exchange of carbon dioxide and oxygen, at
different sites, as hemoglobin molecules flow through the pulmonary capillaries adjacent
to alveolar gas. Carbon dioxide, a waste product of cellular respiration, is unloaded and
oxygen binding to the heme groups of the hemoglobin takes place. From there, oxygen is
delivered to cells for utilization as the final electron acceptor in oxidative
phosphorylation (Weibel 1984; Costanzo 1998).

The Circulation and Oxygen Transport in Blood Vessels
William Harvey (1578-1657) was the first person to accurately describe the
overall workings of the circulatory system. Prior to Harvey, there existed multiple
explanations as to the purpose, source and directional flow of blood, none of them
considering a unidirectional circuit. Galenic physiology taught that there were two types
of blood, the venous and the arterial, each with distinct pathways, independent sources,
and hnctions. Harvey established that the blood must constantly move in a circuit
through the large vessels stemming from the heart and then to the lungs and tissue and
back to the heart again (Porter 1998). What he could not understand then was the
complex system involving vascular networks and oxygen delivery.
In general, blood is propelled from the heart through the arteries (main
distribution vessels) to capillaries (primary exchange vessels) and then into veins

(collecting vessels) which lead back to the heart (Weibel 1984). This is not much more
information than Harvey gleaned from his studies. What he could not see then and what
has become the location and focus of many studies in the circulatory system today is the
microcirculation. The multiple networks are comprised of branching arterioles and still
finer networks of capillaries, vessels whose walls are comprised of only a single layer of
endothelial cells and whose lumen permits red blood cells to pass only in single file
(Berne and Levy 1998; Costanzo 1998).
Capillary structure is maximized for the local diffusion of oxygen down a gradient
into the mitochondria1 sinks created by oxidative phosphorylation (Weibel 1984). Their
walls are thin and they exhibit the greatest surface-area-to-volume ratio in the
microcirculation (Costanzo 1998). In addition, red blood cell velocity is low and gas
diffusion distance is minimized by the close proximity of capillaries to surrounding tissue
cells (Pittman 1995).

Convection and Diffusion
Oxygen is transported via convection (i.e., the movement of oxygen in blood by
bulk flow) and diffusion (i.e., molecular movement of oxygen in the fluid or gas phase
down partial pressure gradient) (Weibel 1984; Pittman 2000). Convective flow of
oxygen can be expressed by the following (Pittman 1995):
Equation 1

where CHbis the oxygen binding capacity of hemoglobin (i.e. the maximum amount of
oxygen that is able to bind to hemoglobin per unit volume of blood (Costanzo 1998),
[H~]RBc
is the concentration of hemoglobin in a single red blood cell, VRBCis the volume
of a single red blood cell, SRRBCis the red blood cell supply rate (cellsls), and SO2 is the
fractional oxygen saturation of the red blood cell hemoglobin.
' ~be~determined
)
by the application of
Diffusive flow of oxygen ( ~ 0 2 ~can
Fick's Principle, a statement of the conservation of mass, by the following:
Equation 2
DIFF -~

Q02

where

~ 0 2 " ~is ~convective
"

0

2

CONV

(upstream)
"
~
~ - QO2
~

(downstream)

flow of oxygen (Pittman 1995; Pittman 2000).

Alternatively, capillary diffusion can be described more directly as the radial diffusive
flux of oxygen as:
Equation 3

~0~~
= - DaAAP021Ax

where ~

0

is the
2 quantity
~
of oxygen moved per unit time, D is the free diffusion

coefficient for a particular molecule, a is the oxygen solubility coefficient, A is the crosssectional area, and AP02/Ax is the partial pressure gradient (i.e., AP02 is the partial
pressure difference of oxygen and Ax is the diffusion distance) (Berne and Levy 1998;
Pittman 2000). The ability for diffusion to function as the primary mechanism in the
exchange of gases, substances, and waste products between the capillaries and the tissue

cells for the entire body, despite large diffusion distances of 80 pm compared to 0.5 pm
in pulmonary capillaries, is due to the large capillary surface area and capillary
recruitment (Berne and Levy 1998).

Artificial Oxygen Carriers
Historical Background
The desire to find safe and effective blood substitutes dates back to the m i d - 1 6 ~ ~
century to the early 17th century (Scott, Kucik et al. 1997; Creteur, Sibbald et al. 2000).
During this time Christopher Wren had been attempting to introduce medicinal liquors
into the bloodstream, believing that the alcoholic spirits could substitute for the vital
"spirit" of the blood (Porter 1998; Creteur, Sibbald et al. 2000). Jean-Baptiste Denis
performed .the first documented successful human-to-human blood transfusion in 1667
(Nucci and Abuchowski 1998).
Modern scientific approaches to replace blood began to be successful in the early
1900s with a better understanding of allogeneic blood transfusion and the function of red
blood cells (Kim and Greenburg 2004). More recently, concerns of long term storage,
supply limitations, and avoidance of disease transmission have fueled the need to develop
blood substitute possibilities. Numerous studies performed throughout the early to mid1900s focused attention on infusing hemoglobin solutions for purposes of trauma
resuscitation to help restore oxygen carrying capacity lost through hemorrhagic shock
(Creteur, Sibbald et al. 2000). Although these investigations resulted in an unexplained

pressor response, altered renal function, and hemoglobinuria, among others, the stage was
set for the development of artificial oxygen carriers (Scott, Kucik et al. 1997; Creteur,
Sibbald et al. 2000).

Major Approaches to Artificial Oxygen Carriers
Under conditions of moderate blood loss where oxygen delivery is not seriously
compromised, intravascular blood volume can be replaced with non-oxygen carrying
plasma expanders. Plasma expanders come in two forms, either as a crystalloid (e.g.,
isotonic saline, Ringer's lactate) or as a colloid (e.g., human serum albumin, dextran,
hetastarch) (Kim and Greenburg 2004). Under conditions of severe blood loss, where
oxygen transport capacity has been reduced below critical levels, an oxygen carrier must
be infused to sustain normal cellular function.
The purpose of artificial oxygen carriers is to act solely as an oxygen-carrying,
volume-replacement solution (Scott, Kucik et al. 1997). The ideal product should have
all of the important properties of red blood cell transfusions including: 1) high oxygen
carrying capacity; 2) transport of oxygen at normal physiological oxygen tensions; 3)
desirable elimination characteristics; 4) low incidence of side effects when properly
screened and administered (Dietz, Joyner et al. 1996). In addition, undesirable properties
should be excluded such as: 1) relatively short shelf-life; 2) antigenicity testing; 3)
transfusion reactions; 4) dependence on a limited donor pool; 5) infectious disease
transmission; 6) immune system suppression (Dietz, Joyner et al. 1996; Scott, Kucik et
al. 1997; Ketcham and Cairns 1999).

Although such a product has been sought for several centuries, it was not until the
1980s and significant investment by the United States military that commercial
development of such a product began (Winslow 2000). Since then, two major
approaches to artificial oxygen carriers have emerged: bio-artificial carriers and synthetic
carriers. Of these, hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon
emulsions (PFCs) are the most promising candidates (Spahn 2000; Kim and Greenburg
2004).
Perfluorocarbons
PFCs are synthetic aromatic carbon-fluorine compounds characterized by a high
gas-dissolving capacity, low viscosity, and biological inertness. These compounds are
emulsified in solution with an agent (58% perfluorooctyl bromide and 2% perluorodecyl
bromide) that allows its dispersal in the blood (Nucci and Abuchowski 1998; Spahn and
Pasch 200 1). PFCs, unlike hemoglobin molecules, do not bind oxygen, but rather they
increase the solubility of oxygen in the plasma (Chang 1999; Ketcham and Cairns 1999).
The oxygen capacity of PFCs is linearly related to PO2, making efficacy of such a
solution dependent on the amount of oxygen available from inspired air (Goodnough,
Scott et al. 1998).
Hemoglobin-based Oxygen Carriers
Currently, HBOCs are developed from stroma-free hemoglobin (SFH). SFH is
derived from human or animal (typically bovine) red blood cells that have been lysed and
the stroma removed through chemical methods, centrifugation, andlor filtration (Haney,

Buehler et al. 2000). However, unmodified SFH has a high oxygen affinity, elevated
intravascular oncotic pressure, and is rapidly cleared through the kidneys (Ketcham and
Cairns 1999; Winslow 2000). Furthermore, the tendency for the hemoglobin tetramer to
dissociate into dimers often results in renal toxicity. For these reasons, chemical or
genetic modifications need to be made to create the desirable oxygen offloading
characteristics, extend the intravascular half-life, and curtail renal toxicity (Kim and
Greenburg 2004).

Hemoglobin-based Oxygen Carriers
ModiJcations of the Hemoglobin Molecule
The high oxygen affinity and subsequent inability of unmodified HBOCs to
efficiently deliver oxygen at tissue sites is due to the loss of 2,3-DPG during the
purification process (Kim and Greenburg 2004). Normally, 2,3-DPG has a specific
binding cleft within the tetrameric hemoglobin molecule which stabilizes the structure in
the deoxy form and promotes positive cooperativity. Without 2,3-DPG oxygen binds to
hemoglobin in the lungs, but will not be unloaded in the tissue (Nucci and Abuchowski
1998; Haney, Buehler et al. 2000). An alternative approach to avoid high oxygen affinity
is to utilize low oxygen affinity bovine hemoglobin as a starting material. Contrary to
human hemoglobin, the affinity of bovine hemoglobin for oxygen is not dependent on
2,3-DPG and can be modified to achieve the desired oxygen affinity and circulation time
(Lee, Atsumi et al. 1989)

A variety of chemical modifications can be made to SFH to adjust the oxygen
affinity to one resembling human encapsulated hemoglobin and to prevent other
undesirable side effects. One method is to bind chemical subgroups to SFH to act in
place of 2,3-DPG (Poly-SFH-P) (Ketcham and Cairns 1999). Another method is to
cross-link the dimers of the hemoglobin tetramer through covalent bonds either
intramolecularly or intermolecularly (commercial examples include diaspirin cross-linked
hemoglobin and rHb1. I). Polymerization is another technique used to link tetramers
together into longer chains (commercial examples include Poly-SFH-P and Oxyglobin),
increasing the overall size of the structure and reducing the possibility of renal filtration
and consequent renal damage (Nucci and Abuchowski 1998; Chang 1999; Ketcham and
Cairns 1999). Conjugating hemoglobin with a polymer such as polyethylene glycol
(PEG) also increases the size of the structure, reduces renal damage, and protects the
molecule from renal excretion (Nucci and Abuchowski 1998; Kim and Greenburg 2004).
More recently, recombinant human hemoglobin is produced by genetically engineered
Escherichia coli bacteria, where the subunits are fused together to prevent tetramer
disassociation (Chang 1999). Lastly, human or animal SFH can be encapsulated in a
phospholipid vesicle, resulting in hemoglobin concentrations and reversible oxygen
binding similar to that of human blood (Kim and Greenburg 2004).

Physiological Effects of HBOCs
A number of physiological side effects and negative attributes have been observed
with HBOCs, despite successful modifications. Animals that have received hemoglobin

solutions maintain normal oxygen consumption and carbon dioxide production, as well as
cardiac output, yet there are increases in mean arterial pressure, pulmonary artery
pressure, and systemic vascular resistance (Dietz, Joyner et al. 1996). The hypertensive
effects are caused by vasoconstriction, with studies observing up to 35% increases in
diastolic and systolic pressures and 45% increases in systemic and pulmonary vascular
resistance (Goodnough, Scott et al. 1998). Mechanisms of the vasopressor effect have
been attributed to nitric oxide (NO) "scavenging" by hemoglobin, excess oxygen delivery
to peripheral tissues, direct effects on peripheral nerves, the oxidative properties of
hemoglobin (Sanders, Ackers et al. 1996), or endothelin release (Gulati, Sharma et al.
1996). However, most investigators have focused on NO interactions with hemoglobin.
NO, once referred to as endothelial derived relaxing factor (EDRF), normally
induces vasodilation, thereby reducing blood pressure by the relaxation of vascular
smooth muscle. With the addition of SFH, NO is believed to interact with bound oxygen
in a process called NO dioxygenation (NOD) resulting in met-hemoglobin (metHb) and
nitrate (NO3]. This process occurs rapidly and in vessels creates a diffusion gradient as
the hemoglobin molecules stream along vessel walls acting as an NO "sink" reducing NO
diffusion to smooth muscle receptors (Olson, Foley et al. 2004). This is known as NO
scavenging. Studies have also suggested unpolynierized hemoglobin molecules may
penetrate into the interstitial space (extravasation), resulting in a more direct interference
with normal vasomotor activity (Ketcham and Cairns 1999; Spahn 2000; Olson, Foley et
al. 2004).

NO scavenging has also been found to cause aggregation of platelets (Ketcham
and Cairns 1999). The usual antiplatelet role of NO is removed due to scavenging by
hemoglobin, resulting in increased platelet aggregation at sites of vascular injury
(Ketcham and Cairns 1999; Creteur, Sibbald et al. 2000). However, hemodilution up to
50% of blood volume replacement with a HBOC should not significantly impair normal
coagulation mechanisms (Kim and Greenburg 2004). Other contraindications of note
include gastrointestinal distress and neurotoxicity (Ketcham and Cairns 1999; Kim and
Greenburg 2004).
Another function of NO to consider is its ability to regulate respiration (Sarti,
Giuffre et al. 2003). NO reversibly inhibits cytochrome c oxidase, the terminal electron
acceptor in the mitochondrial respiration chain, by competing with oxygen (Cleeter,
Cooper et al. 1994; Schweizer and Richter 1994). Nanomolar concentrations of NO have
been found to reversibly inhibit cytochrome c oxidase which inhibits normal
mitochondrial function causing oxygen consumption to decrease (Brown and Cooper
1994). Conversely, it has been demonstrated that the suppression of NO synthesis and
therefore a decreased presence of NO available to act on the mitochondrial respiratory
chain resulted in large increases in oxygen consumption (Shen, Hintze et al. 1995).

Possible Indications for HBOCs
The clinical applications of HBOCs are varied, but much focus is placed on
utilization in the surgical setting, trauma medicine, and military applications. Purposed
applications include use in situations of the following: shocldtrauma, hemodilution,

perioperative use, perfusion of ischemic organs, septic shock, organ transplantation, and
tumor therapy (Dietz, Joyner et al. 1996; Creteur, Sibbald et al. 2000). In addition,
clinical application of HBOCs can be found in stroke, sickle cell crises, anemia, and
patients with multiple red cell surface antibodies (Dietz, Joyner et al. 1996; Chang 1999).
HBOCs are ideal for military and trauma settings as a result of long shelf life (> 1 year) at
room temperature, avoidance of the need to cross-match patients, lack of adverse
transfusion reactions, and minimized risk of disease transmission (Goodnough, Scott et
al. 1998).

Hemodilution
Hemodilution refers to the increase in plasma volume resulting in a reduced
concentration of red blood cells in the blood (hematocrit). Isovolemic hemodilution is
the process of withdrawal of a specified volume of blood and replacement with an equal
volume of fluid, either crystalloids, colloids, or artificial oxygen carrier. Hemodilutions
up to 50% of the red blood cell mass and down to a hematocrit of 9% is well tolerated in
physiological systems and the microcirculation (Habler and Messmer 2000; Tsai and
Intaglietta 2001). The clinical significance of this procedure is that it can significantly
reduce blood transfusion requirements during surgery and can be used in the treatment of
acute ischemic stroke and peripheral arterial occlusive disease, among others (Spahn,
Leone et al. 1994).

Acute nomovolemic hemodilution (ANH) is often carried out in the perioperative
setting. During ANH, a patient's blood is removed immediately before or during surgery
and replaced with another fluid (Fakhry and Sheldon 1995; Scott, Kucik et al. 1997).
Both isovolemic hemodilution and ANH, at mild to moderate levels, result in an
increase in cardiac output and blood flow velocity through the decrease of blood
viscosity. These physiological alterations constitute a compensatory mechanism for the
decrease in arterial oxygen content, so that oxygen delivery is maintained (Spahn, Leone
et al. 1994; Tsai and Intaglietta 2001).

Erythrocyte-associated Transients in PO2
Blood flows in large vessels as a homogeneous mixture where the components,
plasma and red blood cells, cannot be easily distinguished. This trend continues as the
bulk flow of blood moves from arteries to arterioles and finally into capillaries. It is at
the capillary level that the individual red blood cells can be easily discerned from the
plasma spaces around them. The phrase "particulate (or discrete) nature of blood flow"
has been used to describe this phenomenon in capillaries.
In recognition of this phenomenon, in 1977 Hellums proposed the term
"erythrocyte-associated transients" (EATS) (Hellums 1977; Hellums, Nair et al. 1996)
which refers to the fluctuations of POz in a capillary caused by the alternate passage of
individual red blood cells and plasma gaps. Since then, many mathematical models have
been developed to explore the implications of these transients (Federspiel and Sarelius

1984; Federspiel and Pope1 1986; Groebe and Thews 1989; Pope1 1989; Wang and Pope1
1993; Hellums, Nair et al. 1996; Kisliakov 1996; Eggleton, Roy et al. 1998).
These transients are a manifestation of the POs gradients between the plasma and
red blood cells with varying amplitudes dependent on cell spacing, shape, and
orientation. The PO2 gradient is also affected by the diffusion gradient that exists for
oxygen outside of the capillary. In many mathematical models, intracapillary resistance
has been shown to be a sizable contribution to overall resistance to oxygen transport.
This stems, presumably, from the low solubility of oxygen in the plasma, which hinders
diffusive oxygen movement down its gradient from the red blood cell through the
surrounding plasma sheath and plasma gaps into the tissue (Golub and Pittman 2005;
Pittman 2005).

Purpose of the Present Study
In this study 1 set out to observe erythrocyte-associated transients in capillary POz
in the rat spinotrapezius muscle under conditions of isovolemic hemodilution with a nonoxygen carrying plasma expander, Hespan, and a hemoglobin-based oxygen carrier,
Oxyglobin. When using Hespan as the hemodiluent, one might expect cell spacing in
capillaries to increase and intracapillary resistance to oxygen offloading to also increase
as hematocrit and total hemoglobin concentration decreased with isovolemic
hemodilution. A direct consequence of this would be more pronounced transients of
EATS and therefore a greater difference between red blood cell PO2 and plasma PO2.

Conversely, when using an artificial oxygen carrier as the hemodiluent under similar
conditions of isovolemic hemodilution, one might expect an increase in cell spacing but a
decrease in intracapillary resistance to oxygen offloading as a result of an increased
contribution of an oxygen carrier to the plasma. This, in turn, would result in a reduction
in EAT transients.
The purpose of the present study is to apply a detection method previously used
for EATs in the rat mesentery to a skeletal muscle model to answer the following
questions: 1) What happens to EATs with the addition of a non-oxygen carrying plasma
expander, like Hespan, under isovolemic hemodilution?; 2) What happens to EATs with
the addition of an oxygen-carrying plasma expander such as a HBOC under isovolemic
hemodilution?

MATERIALS AND METHODS
Anesthesia and Animal Preparation
Sixteen female Spraque-Dawley rats (Harlan, Indianapolis, IN; weight of 241.8
(SD 14.7) grams, age of 83.4 (SD 6.3) days were housed in plastic isolation containers
with continual ventilation in a climate-controlled room kept at 20-23 "C with a
continuous 12 hr: 12 hr light-dark cycle. Laboratory chow and water were provided ad
libitum under the supervision of a certified animal care technician.
Due to technical limitations, it was not possible to obtain capillary PO2 values
from all animals for which systemic data were obtained. Table 1 catalogs the number of
animals in the groups where systemic and capillary data were acquired.
Initial anesthesia with a combination of Acepromazine (2.5 mglkg) and Ketamine
(75 mglkg) was administered via intraperitoneal (i.p.) injection. A continuous infusion of
Saffan (Alphaxolone 9 mglml and Alphadolone 3 mglml, Schering-Plough Animal
Health, Hertfordshire, England) was used for supplemental anesthetic maintenance
administered intravenously (i.v.) via the cannulated right jugular vein using an infusion
pump (Harvard Apparatus Co., Inc., Dover, Mass.) set at an average of .OOl88 (SD .001)
mllmin. Upon conclusion of experimentation, the animals were euthanized by Euthasol
(Pentobarbital 390 mglml and Phenytoin 50 mglml, Delmarva Laboratories, Inc.,
Midlothian, VA) administration of 0.4 mllkg.

Table 1. Number of animals and capillaries used for systemic and POz
determination.

Control

Step 1

Step 2

Hespan

8/2/26

8/5/26

5/5/53

HBOC

8/2/20

8/5/26

5/5/50

Entries in the Table occur in the format: XNIZ where X = Number of animals with
systemic data; Y = Number of animals with capillary data; Z = Number of capillaries
analyzed from the data set.

Hair between the ventral clavicles and mentum, ventral right groin, and dorsal
regions was removed by electric shears, followed by a depilatory cream (Nair, Church
and Dwight Co., Inc., Princeton, NJ). Afterward, the animal was placed in the supine
position on a metal surgical platform with temperature regulation via automated
electronic controls for cannulations and muscle exteriorization.

Tracheal and Vascular Cannulations
First, to ensure a patent airway and spontaneous room-air breathing, the trachea
was cannulated using a 4 cm length of polyethylene tubing (PE-240, Clay Adams,
Parsippany, NJ). Subsequent cannulation of the right jugular vein with PE-90 tubing and
the left common carotid artery with PE-50 tubing allowed for continuous i.v.
administration of Saffan and arterial pressure monitoring, respectively. Further
cannulations of the left femoral vein and artery were performed using PE-20 and PE- 10
tubing (Clay Adams, Parsippany, NJ), respectively, under a stereo microscope (Nikon
SMZ660, Melville, NY). The femoral artery was used for the withdrawal of blood during
the hemodilution procedure, blood sampling for arterial blood gas measurements (ABL
705, Radiometer America Inc., Westlake, OH), and hemoglobin measurements
(Radiometer OSM3, Radiometer, Crawley, West Sussex, UK). The femoral vein was
utilized for Hespan or HBOC infusion and albumin-bound Pd-porphyrin
phosphorescence probe injection. Heparinized saline (20 units of heparidml of normal
saline) or continuous infusion ensured patency of all vascular lines.

Spinotrapezius Preparation
The use of intravital microscopy techniques require the surgical exteriorization of
the spinotrapezius muscle first described by Gray (Gray 1973). A modification of Gray's
technique was used in which a dorsal midline incision was made from the lumbar to the
cervical region, exposing the underlying superficial connective tissue. The tissue was
removed cautiously, taking care not to damage the thin strap muscle on the left lateral
border running parallel to the spinotrapezius muscle. A pair of curved scissors was used
to separate the muscle from the underlying muscle layers starting at the left lateral border
towards the muscle insertion point on the scapular spine and continuing towards the distal
end of thoracolumbar origination. 5-0 silk was sutured every 1 cm along the strap muscle
as the muscle was separated to ensure minimal trauma to the spinotrapezius and to
facilitate surgical and experimental muscle manipulation. The right lateral border was
excised from the vertebral axis, liberating the muscle except from its scapular attachment,
and likewise sutured. A low-temperature cautery device (Gemini RS-300, Roboz
Surgical Instrument Co., Rockville, MD) was used to staunch any vascular bleeding
during the exteriorization procedure and the tissue was kept moist with frequent
application of normal saline. After exteriorization of the spinotrapezius the animal was
placed on a thermostatic animal platform (Golub and Pittman 2003).

Phosphorescence Intravital Microscope
The preparation was observed with an Ortholux microscope (Leitz, Germany)
configured for epi-illumination through a 100XJ1.30 objective (Leitz, Germany).

Immersion oil was placed between the objective and the Saran covering the
spinotrapezius muscle.
Phosphorescence excitation was achieved with a TTL-modulated DPSS 532 nm
laser (GMS1-038-15T, Lasermate Corp., Pomona, CA) which delivered 60 nJ for a
duration of 10 ps to a 0.9 pm diameter point at 100 Hz. The laser light was reflected by a
dichroic mirror (565 DCLP, Chroma Technology Corp., Rockingham, VT) into the
objective lens, then focused onto the mid-plane of a capillary with an adjustable
correction lens between the laser and the microscope. Off-axis alignment of the laser was
used to eliminate reflection of laser light from the various optical surfaces. A
photomultiplier tube (PMT; R3896 with high voltage socket HC 123-01, Hamamatsu
Corp., Bridgewater, NJ) detected the emitted phosphorescence that was collected by the
lOOX objective. A sliding mirror allowed for either video imaging or phosphorescence
light collection with the PMT. A CCD camera (WAT-902B, Watec Co., Ltd., Japan) and
a 5.6" monochrome LCD monitor (45M056, Imaging Solutions, Inc., Korea) where used
for video imaging and indirect capillary observation.
The signal from the PMT was directed to a modified amplifier (OP37EP, Analog
Devices, Norwood, MA) designed to be a current-to-voltage converter outfitted with a
precision analog switch (ADG419BN, Nonvood, MA) allowing it to be disabled during
the laser pulse generation of 10 ps duration at 100 Hz. Therefore, each phosphorescence
decay curve was recorded from the end of the 10 ps excitation pulse until practical zero
was reached, a requirement for 12-bit resolution. The signal was directed from the
current-to-voltage converter to a 12-bit analog-to-digital converter (PC-MIO- 16E-4,

National Instruments, Austin, TX). The digital data were stored on a Dell PC (Round
Rock, TX).
Data acquisition was controlled by the "DualGetCurve" program written in
LabVIEW (National Instruments, TX) and allowed sampling at 200 kHz with 400 data
points per curve and 100 curves per measurement sequence. Origin 6.1 (OriginLab,
Northampton, MA) was used to analyze acquired data.
The laser light passing through the capillary was detected with a T-5 photodiode
(Intor, Socorro, NM) integrated with a 532 nm laser line filter. The signal collected from
the diode was converted to a voltage with Amplifier B and directed to the second channel
of the analog-to-digital converter and stored in the PC. Both the phosphorescence and
light transmission signals were monitored with an oscilloscope (72-3060, Tenma,
Springboro, OH).
Selection of a capillary for measurements, and positioning the focal plane of the
laser was carried out under transillumination using an OG-570 filter (Edmund Optics,
Barrington, NJ). During periods of capillary POz and light transmission (LT)
measurement, background light sources were minimized to reduce any effect of stray
light. Figure 1 is a schematic diagram of the phosphorescence quenching microscope
setup described above.
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Figure 1. Representative Phosphorescence Intravital Microscope Setup

Solution and Probe Preparations
Preparation of Albumin-bound Pd-porphyrin Phosphorescent Probe
Preparation of 20 ml of albumin-bound phosphorescence probe solution (10
mglml) required binding of 200 mg palladium meso-tetra-(4-carboxypheny1)-porphyrin
(Pd-MTCPP; Oxygen Enterprises, Philadelphia, PA) to 1.32 g bovine serum albumin
(BSA; Fraction V, Sigma, St. Louis, MO). Over a period of approximately 30 min the
Pd-MTCPP was added to a 1 mM BSA solution and stored overnight. This solution was
dialyzed in 1 mM polyvinylpyrrolidine solution (PVP; Sigma-Aldrich, Inc.) and
SpectraIPor-4 membranes to eliminate any unbound Pd-MTCPP from solution. After 18
hr the solution was removed from the dialysis membranes and filtered through a
sterilization filter unit (Nalgene, Rochester, NY). Aliquots of 0.5 ml of the final probe
solution were placed in microcentrihge tubes, flash frozen in liquid nitrogen, and
promptly stored at -80 OC.

Properties and Preparation of 0xyg1obinn
Oxyglobinm(also known as HBOC-30 l), a bovine hemoglobin glutamer
(Biopure, Cambridge, Mass.), is a 7.8 pH solution containing 13 gldl polymerized bovine
hemoglobin in a modified lactated Ringer's solution with an osmolality of 300 mOsmIkg.
The P5()for Oxyglobin is 35 mmHg. Less than 5% of the hemoglobin polymer solution is
comprised of unstabilized tetramers, approximately 50% has a molecular weight between
65 and 130 kD with no more than 10% having a molecular weight >500 kD. Oxyglobin

can be stored at room temperature or refrigerated at 2-30 "C for up to 36 months. Plasma
half-life is estimated to range between 18 and 43 hours for dosages of 10-30 mllkg in
dogs.

Heparinized Saline
Heparinized saline was necessary to assure patency of cannulas with intravascular
placement. The solution was prepared using 5 ml heparin solution (100 unitslml; Heparin
Lock, BD, Franklin Lakes, NJ) per 20 ml0.9% NaCl normal saline solution. Only 1 ml
syringes were used for each cannulated vessel.

Hespan
Hespan (Abbott Laboratories, Chicago, IL) belongs to the class of drugs called
plasma volume expanders and consists of 6% hetastarch in a 0.9% sodium chloride
solution. It is a nonpyrogenic, sterile fluid isosmotic with blood (3 10 mOsm/l) and has
no significant oxygen-carrying capacity.

POz Measurements
Capillary Selection and Probe Administration
Before the partial pressure of oxygen (PO2)was measured, each capillary
considered had to meet the following specified selection criteria: 1) sufficient light
transmission (LT) with evident red blood cell (RBC) fluctuations as observed on the

oscilloscope, 2) continuous RBC flow, 3) surface capillary, and 4) three-dimensional
capillary isolation from other microvessels, arterioles, and venules. After capillary
selection, PO2 was determined in each capillary using the phosphorescence quenching
method for intravital microscopy (Zheng, Golub et al. 1996). Measurements were made
in the centerline of the capillary in a region of high epi-illumination and visual contrast.
The phosphor probe (30 mglkg) was administered via the right femoral vein prior
to taking measurements. Approximately one minute of equilibration time was allowed
before initiation of PO2 measurements.

Phosphorescence Quenching Microscopy (PQM)
PO2 determination using PQM is based on 02-dependent quenching of
phosphorescence from photoexcited Pd-porphyrin. The Stern-Volmer equation defines
the relationship between phosphorescence lifetime (z) and PO2 as follows:
Equation 4

l/z

=

l/z, + kqP02

where z, (546 ps) is the lifetime of phosphorescence decay in the absence of 0 2 and k, is
the quenching coefficient (3.06.10~p s - l r n m ~ ~ - 'Phosphorescence
).
decay curves were
analyzed using a non-linear curve fitting the Rectangular distribution model in Origin 6.1
software (Microcal Software Inc., Northampton, MA) as developed by Golub et al.
(Golub, Pope1 et al. 1997):

Equation 5

where t (ps) is the time from the beginning of phosphorescence decay, I(t) (volt) is the
magnitude of the phosphorescence signal, I(0) (volt) is the amplitude of the
phosphorescence signal at t = 0, M (mmHg) is the mean PO2, 6 (mmHg) is the half width
of the POz distribution, T (ps) is the lifetime of the fast post-excitation transient, A (volt)
is the amplitude of the fast post-excitation transient and B (volt) is the baseline offset.
Constants ko = 18.3.10~ps-' and k,

= 3.06.10~p

~ - ~ r n rwere
n ~ ~determined
~'
by Zheng et

al. (Zheng, Golub et al. 1996). A representative plot, Figure 2, illustrates this
relationship.
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Figure 2. Representative phosphorescence decay curve.

The phosphorescence decay curve shown on a logarithmic scale is composed of 400
connected data points taken at 200 kHz over 2000 ps. The decay curve was analyzed
using a non-linear curve fitting the Rectangular distribution model and is shown here by
the continuous line fit.

Light Transmission, Phosphorescence Amplitude Measurements, and
PO2
In order to detect fluctuations of PO2 in the detection volume associated with the
presence of RBCs or plasma gaps, light transmission (LT) and phosphorescence
amplitude (PA) were measured.
LT was measured via photodiode registration of the intensity of the laser light
passing through a capillary and the data collected by the "DualGetCurve" program.
Maximum PA was determined from analyzing the beginning of the decay curve after the
end of the excitation pulse. The maximum amplitude of the phosphorescent signal is
proportional to the amount of plasma present in the detection volume, because the probe
is homogeneously dissolved in plasma and does not enter RBCs. This was demonstrated
using densitometric scanning and phosphorescence imaging of the Pd-porphyrin probe
location that detected the presence or absence of RBCs (Golub and Pittman 2005).
Upon analysis, the maximum amplitude of the phosphorescence decay curve (PA)
and the light transmittance pulses were averaged using the three highest points at the peak
of each signal. Noise from LT, PA, and PO2 values was reduced by filtering the signal
with a fast Fourier transform filter (FFT; Origin 6.1, OriginLab, Northampton, MA) with
50 Hz and 20 Hz cutoff frequency filtering.
Although 100 individual PO2 measurements were made over the 1 s time course, a
system was derived to choose which capillaries and PO2 measurements to calculate
across the 1 s data collection interval. Golub and Pittman (2005) made two conclusions

that provided selection parameters for PO2 calculation: 1) high positive correlations
between PA and LT predicted the presence of EATS; 2) PA and PO2 had a more
significant negative correlation than LT and PO2 indicating PA is a more consistent
predictor of whether or not a RBC is in the detection region. With these parameters in
mind, capillary selection was based on the highest correlation coefficients for each
condition. Furthermore, capillary PO2 for red blood cells and plasma gaps was
determined using the ten lowest PA values and the ten highest PA values, respectively,
from the 100 collected data points. This corresponds to the idea that high PA should
indicate the presence of plasma in the detection volume and low PA should indicate the
presence of a RBC in the detection volume.
Of the total 3 19 capillaries that were measured, 201 capillaries were chosen to
determine POz values corresponding to the combined 20 high and low PA values. Each
of the PO2 calculations using Origin 6.1 (OriginLab, Northampton, MA) took
approximately two minutes.

Mean Arterial Pressure
Mean arterial pressure (MAP) was continuously monitored from the right
common carotid artery using the CyQ 1031301 acquisition and display system
(CyberSense Inc., Nicholasville, KY). Specific measures of MAP were recorded under
control conditions and after a 10 min stabilization period subsequent to each
hemodilution step.

Hernodilution Procedure
Isovolemic hemodilution was accomplished by the exchange of a given volume of
blood with an equal volume of fluid (e.g., colloid, crystalloid, artificial oxygen carrier),
resulting in decreased hematocrit, while maintaining a constant total blood volume.
During this study, a two step withdrawallinfusion process was utilized with each step
taking approximately forty-five minutes to complete. Additionally, each of these steps
was reached by dividing the hemodilution volumes into four discrete withdrawallinfusion
volumes.
Isovolemic hemodilution was achieved through the withdrawal of blood from the
right femoral artery followed by infusing the hemodiluent into the right femoral vein.
The hematocrit of each animal was systematically lowered through two hemodilution
steps: from 39.5
mean
mean

* 2.7 % (Control, mean * SD) to hematocrit of 27.5 * 2.8 % (Step 1,

SD for both hemodiluents) and then to a hematocrit of 13.5 h 2.1 % (Step 2,

* SD for both hemodiluents).
In using this "discrete" method of hemodilution the effective blood volume

associated with hemodilution, Ve, was initially determined by:
Equation 6

VB = P o WB

where /?is a proportionality factor in mllg and WBis the body weight of the animal in
grams. A proportionality factor of 0.06 mllg was used for these experiments.

Determination of initial systemic hematocrit, HI, and final systemic hematocrit,
HF, was achieved through a centrifuged 75 pl sample collected from the right femoral
arterial line in a heparinized microhematocrit capillary tube (Scientific Products, McGaw
Park, IL). Assessments of systemic hematocrit were performed at control conditions and
after hemodilution Steps 1 and 2.
The target value of HFafter each hemodilution step was defined by the following
equation:
Equation 7

where VHDis the hemodilution volume. This volume of blood is withdrawn and replaced
with an equal volume of hemodiluent. Therefore, the volume of blood that needs to be
removed and then replaced is:
Equation 8

PO2 measurements were made during control conditions (N = 16) and after
hemodilution Step 2 in ten animals, five for each Hespan and Oxyglobin conditions. PO2
measurements were also made after the intermediate hemodilution Step 1, eight for each
Hespan and Oxyglobin conditions.

Statistics
Data within these experiments are shown as mean h standard deviation in tables
and mean

* error in figures.

One Way Analysis of Variance (ANOVA) was conducted

with the software JMP version 4 (SAS Institute Inc., Cary NC) to assess statistical
significance for the means of each experimental condition. Statistical significance
between PO2 values in the different hemodilution steps was determined using Tukey's
Multiple Comparison test. Additional testing of APO2 values in the different
hemodilution steps was accomplished with a Student's t-test. Linear regression statistics
were also calculated using JMP version 4. Statistical significance was taken to be p <
0.05.

RESULTS
Phosphorescence Amplitude, Light Transmission and PO2
An example of simultaneous one second recordings containing 100 consecutive
points for measurements of PO2, PA, and LT are shown in Figure 3 for a single capillary
after Step 1 of isovolemic hemodilution with Hespan. The PA and LT signals changed in
parallel while there were inverse temporal variations of PO2 that occurred in comparison
to the PA and LT signals. This is demonstrated quantitatively in Figure 4 and Figure 5
which yielded the following correlation coefficients: 0.905 for PA versus LT, -0.354 for
PO2 versus LT, and -0.244 for PO2 versus PA. Similar PA and LT modulations were
observed in other capillaries (n = 101). In capillaries where all PO2 measurements (100
data points generating 100 distinct PO2 measurements) were analyzed (n = 5), similar
modulations in comparison to the single time course presented in Figure 3 were also
observed.
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Figure 3. Example of P02, light transmission, and phosphorescence amplitude
versus time.
Tracings represented by the non-smoothed lines represent simultaneous one second
recordings containing 100 consecutive data points taken from a stationary observation
point in a capillary. Smoothed line represents the data using a 50-20 Hz fast Fourier
transform (FFT). See text for further explanation.
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Figure 4. Plot of phosphorescence amplitude versus light transmission.
PA and LT data are from a simultaneous one second recording containing 100
consecutive data points taken from a stationary observation point in a capillary and
plotted here against each other. See text for further explanation.
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Figure 5. Plots of partial pressure of oxygen versus phosphorescence amplitude and
light transmission.

Effects of Hemodilution with Hespan and Oxyglobin on Systemic
Variables
Mean Arterial Pressure and Hematocrit
Systemic hematocrit was reduced in two steps to 26.3 h 2.5 % (Step 1) and then to

*

14.6 2.3 % (Step 2) through isovolemic hemodilution with Hespan. In a separate group
of animals, systemic hematocrit was reduced to 28.6

* 2.6 % (Step 1) and then to 12.3 *

1.1 % (Step 2) through isovolemic hemodilution with Oxyglobin. A Control value of
39.5

* 2.7 % was used for comparisons with both Hespan and Oxyglobin groups. As

hematocrit was reduced using Oxyglobin as the hemodilution fluid, the mean arterial
pressure increased from 102.9

* 10.2 mmHg (Control) to 124.4 * 21.5 mmHg (Step 1)

and even further to 135.8 h 17.7 mmHg (Step 2). Mean arterial pressure increased when

* 10.2 mmHg (Control) to 105.1 h
16.9 mmHg (Step 1) and decreased after Step 2 to 97.4 * 15.6 mmHg. The values for

Hespan was used as the hemodilution fluid from 102.9

systemic hematocrit and mean arterial pressure for Control, Step 1, and Step 2 for both
Hespan and Oxyglobin are presented in Table 2 and in graphic form in Figure 6.
One Way Analysis of Variance yielded statistically significant differences
between Control, Step 1, and Step 2. Tukey's Multiple Comparisons test revealed
significant differences with mean arterial pressure values between Control and Steps 1
and 2 in the Oxyglobin group. Tukey's test also revealed significant differences of
Oxyglobin Step 2 to both Hespan Steps 1 and 2, while Step 1 of hemodilution with
Oxyglobin was significant to Hespan Step 1.

Table 2. Mean (k standard deviation) systemic data for all animals.
Oxyglobin

Hespan HD2

Oxyglobin

MAP = Mean arterial pressure (mmHg); PaOz= Systemic arterial partial pressure of
oxygen (mmHg); S,Oz = Arterial oxygen saturation (%); P&02 = Systemic arterial
partial pressure of carbon dioxide (mmHg); pHa = Systemic arterial pH; [Hb] = Total
hemoglobin concentration (gldl); Hct = Systemic hematocrit (%); MCHC = Mean
corpuscular hemoglobin concentration (gldl); [HbIRsc = Red blood cell hemoglobin
= Plasma hemoglobin concentration (gldl); HD 1 =
concentration (gldl); [Hb],l,,,
Hemodilution Step 1; HD2 = Hemodilution Step 2; N = Number of animals.
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Figure 6. Plot of mean arterial pressure versus hematocrit for hemodilution with
Hespan and Oxyglobin.
The filled circle represents the Control value, the filled and open triangles represent the
HBOC Oxyglobin values at Step 1 (HB1) and Step 2 (HB2), respectively, and the filled
and open squares represent Hespan values at Step 1 (HS1) and Step 2 (HS2),
respectively. Standard error bars are shown.

* = Significantly different from Control (p<0.05)
# = Significantly different from both Hespan Steps 1 and 2 (p<0.05)

1- = Significantly different from Hespan Step 2 ( ~ ~ 0 . 0 5 )

Mean Arterial Pressure and Plasma Hemoglobin
The plasma hemoglobin concentration increased from an assumed value of 0 gldl
(Control) to 3.7 5 1.7 gldl in Step 1 and then to 8.0 h 0.4 gldl in Step 2 for hemodilution
with Oxyglobin. As plasma hemoglobin concentration incrqased, the mean arterial
pressure increased from 102.9

* 10.2 mmHg (Control) to 124.4 % 21.5 mmHg after Step1

and then to 135.8 5 17.7 mmHg after Step 2 of the isovolemic hemodilution procedure
with Oxyglobin. Step 1 and Step 2 for Hespan are not shown because Hespan makes no
contribution to plasma hemoglobin concentrations. Linear regression statistics revealed a
correlation of 0.662 and p value of < 0.0001. These results are presented in Table 3 and
summarized in graphic form in Figure 7.

Effects of Hemodilution with Hespan and Oxyglobin on PO2 in
Capillaries
Red Blood Cell PO2 and Comparisons with Hematocrit, Total Hemoglobin
Concentration, and Plasma Hemoglobin Concentration
Results for the subset of data in which PO2 was measured in capillaries are contained in
Table 3 and Table 4.
Red Blood Cell PO2 and Hematocrit
Red blood cell PO2 decreased from 54.9 5 14.6 mmHg (Control) to 36.7 =t18.4
mmHg (Step 1) then to 22.2 5 2.5 mmHg (Step 2) as the hematocrit was reduced from
38.8

* 1.9 % (Control) to 23.8 h 2.5 % (Step 1) then to 14.6 5 2.3 % (Step 2) through

isovolemic hemodilution with Hespan. Hemodilution with Oxyglobin exhibited

Table 3. Mean (hstandard deviation) systemic data for animal sub-group.

oxyglobin Q
T

1

I

Hespan HDZ

roxyglobin JIDZ

Hct

MAP = Mean arterial pressure (mmHg); Pa02= Systemic arterial partial pressure of oxygen (mmHg); SaOz= Arterial oxygen
saturation (%); PaC02 = Systemic arterial partial pressure of carbon dioxide (mmHg); pHa = Systemic arterial pH; [Hb] =
Total hemoglobin concentration (gldl); Hct = Experimental animal systemic hematocrit (%); MCHC = Mean corpuscular
hemoglobin concentration (gldl); [HbIRBC= Red blood cell hemoglobin concentration (gldl); [Hb],la,,a = Plasma hemoglobin
concentration (gldl); N = Number of animals; n = Number of capillaries; HD1 = Hemodilution Step 1; HD2 = Hemodilution
Step 2.
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Figure 7. Plot of plasma hemoglobin concentration versus mean arterial pressure
for hemodilution with Oxyglobin.

HB1 = HBOC Oxyglobin Step 1, HB2 = HBOC Oxyglobin Step 2. Standard error bars
are shown.

Table 4. Mean (*standard deviation) partial pressure of oxygen data for animal sub-group.
Control
(N=4)

Hespan HD1
(N=2)

Oxyglobin HD1
(N=2)

46

26

26

Hespan HD2

Oxyglobin HD2
(N=5)
50

RBC PO2

N = Number of animals; n = Number of capillaries; HD1 = Hemodilution Step 1; HD2 = Hemodilution Step 2; PG PO2 =
Plasma gap partial pressure of oxygen; RBC PO2 = Red blood cell partial pressure of oxygen; AP02 = Difference between
RBC PO2 and PG PO2; P,02 = Mean capillary PO2.

$ = Significantly different from Control (p<O.O5)

* = Significantly different from zero (p<0.05)
** = Significantly different from zero (p<0.0001)

a decrease in red blood cell PO2 from 54.9 k 14.6 mmHg (Control) to 34.4 k 10.1 mmHg
(Step 1) then to 11.6 k 11.O mmHg (Step 2) as the hematocrit was reduced from 38.8 k
1.9 % (Control) to 28.1 k 1.5 % (Step 1) and then to 12.3 k 1.1 % (Step 2). A graphic
presentation of these data is found in Figure 8.
A Bivariate Linear Fit Model with subsequent Analysis of Variance revealed a
statistically significant difference between the linear regressions of Hespan and
Oxyglobin for red blood cell PO2 versus hematocrit.
Red Blood Cell PO2 and Total Hemoglobin Concentration

Red blood cell PO2 decreased from 54.9 k 14.6 mmHg at a total hemoglobin
concentration of 13.5 k 0.6 gldl to 36.7 k 18.4 mmHg at a total hemoglobin concentration
of 10.8 k 4.7 gldl after Step 1, and then to 22.2

* 10.6 mmHg at a total hemoglobin

concentration of 5.1 k 0.8 gldl after Step 2 of Hespan hemodilution. Red blood cell PO2
sustained a steeper decline when using Oxyglobin as the hemodilution fluid beginning
with the same Control values as stated previously to a PO2 of 34.4 k 10.1 mmHg at a total
hemoglobin concentration of 13.1 k 0.4 gldl after Step 1 and then to a PO2 of 11.6 k 11.O
mmHg at a total hemoglobin concentration of 11.3 k 0.5 gldl after Step 2. A graphic
presentation of these data is found in Figure 9.

Hewan
RBC PO, = 1.33*Hct + 3.57
R = 0.997
P = 0.0496
Oxvelobin
RBC PO, = 1.62*Hct + -9.19
R = 0.997

Hct (%)

Figure 8. Plot of red blood cell partial pressure of oxygen versus hematocrit for
hemodilution with Hespan and Oxyglobin.
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown. Linear regression lines are
shown for Hespan and Oxyglobin as hematocrit was reduced.
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Figure 9. Plots of red blood cell partial pressure of oxygen versus total hemoglobin
for Hespan and Oxyglobin.
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.

Red Blood Cell POz and Plasma Hemoglobin Concentration
Figure 10A graphically presents red blood cell PO2 at a plasma hemoglobin
concentration of 0 gldl for Control and hemodilution Steps 1 and 2 for Hespan. During
isovolemic hemodilution with Hespan, the red blood cell PO2 decreased from 54.9
mmHg (Control) to 36.7

* 14.6

* 18.4 mmHg (Stepl) and then to 22.2 * 10.6 mmHg after Step

2. Figure 10B depicts the decrease of red blood cell PO2 with increasing plasma
hemoglobin concentration for hemodilution with Oxyglobin. In this case, red blood cell
PO2 decreases from 54.9
to 11.6

* 14.6 mmHg (Control) to 34.4 * 10.1 mmHg (Step 1) and then

* 11.O mmHg (Step 2).

Plasma Gap PO2 and Comparisons with Hematocrit, Total Hemoglobin
Concentration, and Plasma Hemoglobin Concentration
Plasma Gap POz and Hematocrit
With a decrease in hematocrit from 38.3

1.9 % (Control) to 23.8

* 2.5 % (Step

*
decreased from 45.1 * 12.9 mmHg (Control) to 35.2 h 18.0 mmHg (Step 1) and then to
20.9 * 10.3 mmHg (Step 2). Oxyglobin plasma gap PO2 values decreased to 32.8 h 10.0
mmHg with a hematocrit of 28.1 * 1.5 % after Step 1 to a plasma gap PO2 of 11.6 * 11.0
mmHg and hematocrit of 12.3 * 1.1 % after Step 2. Hematocrit can be found in Table 3
1) and then to 14.6 2.3 % after Step 2 of Hespan hemodilution, the plasma gap PO2

(p. 42) and plasma gap PO2 can be found in Table 4 (p. 44). These data are also
presented in graphic form in Figure 11.

Control
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L-J
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Figure 10. Plots of red blood cell partial pressure of oxygen versus plasma
hemoglobin for Hespan and Oxyglobin.
HSl = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.
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Figure 11. Plot of plasma gap partial pressure of oxygen versus hematocrit for
hernodilution with Hespan and Oxyglobin.
HSl = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown. Linear regression lines are
shown for Hespan and Oxyglobin as hematocrit was reduced.

A Bivariate Linear Fit Model with subsequent Analysis of Variance revealed a
statistically significant difference between the linear regressions of Hespan and
Oxyglobin for plasma gap PO2 versus hematocrit.
Plasma Gap PO2 and Total Hemoglobin Concenttation
As the total hemoglobin concentration decreased from 13.5 + 0.6 gldl (Control) to

* 0.8 gldl (Step 2), the plasma gap PO2 decreased
from 45.1 * 12.9 mmHg (Control) to 35.2 * 18.0 mmHg (Step 1) and then to 20.9 f 10.3
10.8 + 4.7 gldl (Stepl) and then to 5.1

mmHg (Step 2) when using Hespan as the hemodilution fluid. In the case of Oxyglobin,
there was a decrease in plasma gap PO2 from 45.1 k 12.9 mmHg (Control) to 32.8

10.0

mmHg (Stepl) and then to 11.6 f 1.2 mmHg after Step 2 hemodilution over a change in
total hemoglobin concentration from 13.5 k 0.6 gldl (Control) to 13.1 f 0.4 gldl (Step 1)
and then to 11.3 k 0.5 gldl (Step 2). Total hemoglobin concentrations can be found in
Table 3 (p. 42) and plasma gap PO2 can be found in Table 4 (p. 44). These data are also
presented in graphic form in Figure 12.

Control

HS2

40
35

Figure 12. plots of plasma gap partial pressure of oxygen versus total hemoglobin
for Hespan and Oxyglobin.
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HBl = HBOC Oxyglobin Step 1, HB2
HBOC Oxyglobin Step 2. Standard error bars are shown.

=

Plasma Gap POz and Plasma Hemoglobin Concentration
Control plasma gap PO2 was 45.1 k 12.9 mmHg at an assumed plasma
hemoglobin concentration of 0 gldl. Plasma gap PO2 for Hespan Steps 1 and 2 decreased
from Control to 35.2 h 18.0 mmHg and 20.9 i 10.3 mmHg, respectively, also at plasma
hemoglobin concentrations of 0 gldl. Using Oxyglobin as the hemodilution fluid, plasma
hemoglobin concentrations increased from 5.3 i 1.5 gldl (Step 1) to 8.0 h 0.4 gldl (Step
2) and plasma gap PO2 decreased to 32.8 i 10.0 mmHg (Step 1) and then to 11.6 i 1.2
mmHg (Step 2). Plasma hemoglobin concentrations can be found in Table 3 (p. 42) and
plasma gap PO2 can be found in Table 4 (p. 44). A graphic representation of these data is
found in Figure 13.

Red Blood Cell - Plasma Gap PO2 Difference (APOJ and Comparisons with
Hematocrit, Total Hemoglobin Concentration, Plasma Hemoglobin
Concentration, and Red Blood Cell PO2
APOz and Hematocrit
Using Hespan as the hemodilution fluid, hematocrit decreased from 38.8 h 1.9 %
(Control) to 23.8 k 2.5 % (Step 1) and then to 14.6 i 2.3 % (Step 2) while AP02
decreased from 9.7 i 9.1 mmHg (Control) to 6.2 k 9.2 mmHg (Step 1) and then to 1.3 i
2.0 mmHg (Step 2). Using Oxyglobin as the hemodilution fluid, hematocrit decreased
from 28.1 h 1.5 % (Step 1) to 12.3 i 1.1 % (Step 2), while AP02 decreased to 1.6 i 2.6
mmHg (Step 1) and then to 0.0 i 1.1 mmHg (Step 2) from 9.7 k 9.1 mmHg (Control).
Hematocrit can be found in Table 3 (p. 42) and AP02 can be found in Table 4 (p. 44).
These data are also presented in graphic form in Figure 14.
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Figure 13. Plots of plasma partial pressure of oxygen versus plasma hemoglobin for
Hespan and Oxyglobin.

HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.
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Figure 14. APOz versus hematocrit.

HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.

AP02 and Total Hemoglobin Concentration
The total hemoglobin concentration was decreased during isovolemic

*

hemodilution with Hespan from 13.5 h 0.6 gldl (Control) to 10.8 4.7 gldl (Step 1) and

* 0.8 gldl (Step 2). During this time the AP02 decreased from 9.7 k 9.1
mmHg (Control) to 1.6 * 5.4 mmHg (Step 1) and then to 1.3 * 2.0 mmHg (Step 2). The

then to 5.1

total hemoglobin concentration decreased during isovolemic hemodilution with

*

Oxyglobin from 13.5 0.6 gldl (Control) to 13.1 0.4 gldl (Step 1) and then to 11.3 f
0.5 gldl (Step 2). The AP02 decreased from 9.7 h 9.1 mmHg (Control) to 1.6 h 2.6
mmHg (Step 1) and then to 0.0 f 0.8 mmHg (Step 2) using Oxyglobin as the
hemodilution fluid. Total hemoglobin concentration can be found in Table 3 (p. 42) and
A PO2 can be found in Table 4 (p. 44). These data are also presented in graphic form in
Figure 15.
AP02 and Plasma Hemoglobin Concentration
AP02 decreased from 9.7 h 9.1 mmHg (Control) at a plasma hemoglobin
concentration of 0 gldl to 1.6 f 5.4 mmHg (Step 1) and then to 1.3 f 2.0 mmHg (Step 2)
with corresponding plasma hemoglobin concentrations of 0 gldl (Steps 1 and 2) for
Hespan isovolemic hemodilution. For Oxyglobin, APO2 decreased to 1.6 f 2.6 mmHg
(Step 1) and then to 0.0 f 1.1 mmHg (Step 2) from Control with corresponding plasma
hemoglobin concentrations of 5.3 f 1.5 gldl (Step 1) and 8.0 f 0.4 gldl (Step 2). Plasma
hemoglobin concentration can be found in Table 3 (p. 42) and AP02 can be found in
Table 4 (p. 44). These data are also presented in graphic form in Figure 16.
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A HB2

Figure 15. APOz versus total hemoglobin concentration.

HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are show
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Figure 16. AP02 versus plasma hemoglobin concentration.

HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.

AP02 and Red Blood Cell POz
Red blood cell PO2 and AP02 were highest at the Control values of 54.9 h 14.6
mmHg and 9.7 h 9.1 mmHg, respectively. Red blood cell PO2 and AP02 decreased to

*

36.7 h 18.4 mmHg and 1.6 5.4 mmHg, respectively, after Step 1 of Hespan
hemodilution. Red blood cell PO2 and AP02 decreased to 22.2 h 10.6 mmHg and 1.3

*

2.0 mmHg, respectively, after Step 2 of Hespan hemodilution. With Oxyglobin as the
hemodilution fluid, red blood cell PO2 and AP02 decreased from Control to 34.4

* 10.1

*

mmHg and 1.6 2.6 mmHg, respectively, after Step 1 and then to a red blood cell PO2 of
11.6 h 11.0 mmHg and APOz of 0.0

* 1.1 mmHg after Step 2. Red blood cell PO2and

AP02 can be found in Table 4 (p. 44). These data are also presented in graphic form in
Figure 17.

Results of Statistical Analysis
A One Way Analysis of Variance revealed that all values for Hespan and
Oxyglobin for both Steps 1 and 2 were significantly different from Control for plasma
gap PO2 and red blood cell PO2 with all p-values less than 0.05. In addition, for both
plasma gap PO2 and red blood cell PO2, Tukey's Multiple Comparisons test revealed
significant differences between all values except among Hespan and Oxyglobin Step 1.
Students t-tests determined significant differences between plasma gap PO2 and red blood
cell PO2 (AP02) in the Control group (p<0.0001), hemodilution Step 1 with Oxyglobin
(p<0.05), and hemodilution Step 2 with Hespan (p<0.000 1).

Figure 17. A P 0 2 versus red blood cell partial pressure of oxygen.
HS 1 = Hespan Step 1, HS2 = Hespan Step 2, HB 1 = HBOC Oxyglobin Step 1, HB2 =
HBOC Oxyglobin Step 2. Standard error bars are shown.

DISCUSSION
Theoretical models have predicted the existence of intracapillary PO2 gradients
that take into account the discrete nature of blood flow in capillaries. Hellums was the
first to do so in 1977 (Hellums 1977). The first experimental evidence to support these
predictions determined that plasma POz gradients do exist in the form of erythrocyteassociated transients or EATs (Golub and Pittman 2005). The purpose of the present
study was to observe EATs in skeletal muscle capillaries. Furthermore, the purpose
extended towards describing the nature of EATs under isovolemic hemodilution
conditions with Hespan and a hemoglobin-based oxygen carrier. By employing the Pdporphyrin phosphorescence quenching method (PQM) along with measuring light
transmission, it was possible to determine the relative presence or absence of red blood
cells in the detection volume over a one second time course.
There were three major findings from this study and multiple minor findings that
will be discussed in this section. The first major finding is that EATs can be measured in
skeletal muscle using prior detection methods as were applied to the rat mesentery
(Golub and Pittman 2005). Secondly, the magnitude of EATs depends on capillary POz
values. Thirdly, the magnitude of EATs is dependent on hematocrit and plasma
hemoglobin concentration and that these values vary depending on the hemodilution fluid
used.

Prior Documentation on Erythrocyte-Associated Transients,
Hemodilution and Hemoglobin-Based Oxygen Carriers
The present study is unique for several reasons. Although the description of
intracapillary PO2 heterogeneity (Hellums 1977; Homer, Weathersby et al. 198 1) allowed
a framework for mathematical modeling which predicted the presence of PO2 gradients
between M C s and plasma (Federspiel and Sarelius 1984; Federspiel and Pope1 1986;
Hellums, Nair et al. 1996), Golub and Pittman (2005) collected the first experimental data
from capillaries in the rat mesentery, demonstrating the existence of EATS. The present
investigation used the rat spinotrapezius muscle and made measurements under
hemodilution conditions with two hemodiluents for the first time.

Phosphorescence Amplitude and Light Transmission
Laser excitation of the Pd-porphyrin phosphorescent probe confined to the plasma
allowed the measurement of plasma PO2 transients and the determination of
phosphorescence amplitude (PA). The discrete nature of blood flow was also revealed by
the simultaneous measurement of light transmission (LT) through the capillary. As a
result of the intrinsic nature of red blood cells (RBC) to absorb light, the signal would
decrease in the presence of a IU3C and increase once the RBC moved out of the detection
region. The signal for PA would correspondingly increase, reflecting the presence of
plasma measured by the amount of light emitted by the excited phosphor probe in the
detection region, and decrease when an IU3C was present (i.e., less plasma).

Ideally, PA and LT amplitude fluctuations would correspond exactly. Although
these two independent variables were sometimes highly correlated, this was not always
the case. Golub and Pittman (2005) found that, due to the complex refraction of
transmitted light by a RBC with random size, shape, and orientation and possible
misalignment of the photodiode used to measure LT under the tissue, PA was a better
indicator of the presence of plasma or RBCs. Other factors that might contribute to
variability between these two factors in skeletal muscle are muscle thickness, refraction
of transmitted light by muscle tissue, and the presence of multiple microvessels along the
incident light beam.
The expectation for the isovolemic hemodilution protocol with Hespan was that
LT and PA signal tracings would be more pronounced with troughs and peaks becoming
more widely spaced. The expectation for the isovolemic hemodilution protocol with
Oxyglobin was that PA signal tracings would show a decreased distinction between
troughs and peaks, resulting from the increased plasma hemoglobin concentration.
Neither of these expectations was observed in reviewing LT and PA signal
tracings from Control and Steps 1 and 2 for hemodilution with either Hespan or
Oxyglobin. In fact, the relative spacing of plasma gaps and RBCs remained relatively
unchanged from Control to hemodilution conditions. This could be explained in part by
the observation of capillary networks during experimentation where RBCs did not appear
to be distributed uniformly in all capillaries; rather, some capillary networks became
plasmatic while other capillaries maintained a relatively normal RBC flow.

It is also interesting to note that in multiple capillaries the PA signal population
appeared to be bimodal. One possible explanation for this is that the two separate
populations represent values corresponding to RBCs and plasma gaps (Figure 18). This
explanation corresponds to previously presented ideas that the LT and PA signals should
be higher when the detection volume is comprised of plasma and lower when a RBC is
present.

Effects of Hemodilution on Systemic Parameters
Summary of Experimental Results for Mean Arterial Pressure and Hematocrit
Hemodilution with Hespan resulted in an overall decrease in mean arterial
pressure as the hematocrit was reduced. For Hespan, mean arterial pressure went from

* 10.2 mmHg (Control) to 105.1 * 16.9 mmHg (Step 1) and decreased after Step 2
to 97.4 * 15.6 mmHg. In the case of hemodilution with Oxyglobin, a progressive
102.9

increase in mean arterial pressure occurred as the hematocrit was reduced. For
Oxyglobin, mean arterial pressure went from 102.9 + 10.2 mmHg (Control) to 124.4
21.5 mmHg (Step 1) and even further to 135.8

*

* 17.7 mmHg (Step 2). The infusion of

Oxyglobin caused an immediate and statistically significant increase in mean arterial
pressure following hemodilution Step 1. After Step 2 hemodilution there was a sustained
increase in mean arterial pressure, yet the difference between MAP for Step 1 and Step 2
was no longer significant. The means for both Oxyglobin Steps 1 and 2 were
significantly different from the MAP for Hespan Step 2.

Explanation of Variation in Results
In several of the Hespan experiments leading to Step 1 measurements and in
several of the Oxyglobin experiments leading to Step 2 measurements, technical
difficulties regarding the wi thdrawallinfusion protocol caused an overshoot in
hemodilution. In both animals of the Hespan Step 2 group, hematocrit was substantially
lower than the target hematocrit of 30% (22% and 25%) and, in three of five animals for
the Oxyglobin Step 2 group, hematocrit was lower than the target hematocrit of 15%
(1 I%, 12%, and 12%). There was also an unexplained rise in mean arterial pressure for
hemodilution Step 1 using Hespan as the hemodilution fluid (see Figure 6, p. 40).

Summary of Experimental Results for Mean Arterial Pressure and Plasma
Hemoglobin Concentration
Isovolemic hemodilution with Oxyglobin caused an increase in plasma
hemoglobin concentration as expected from the assumed value of 0 gldl (Control) to 3.7 h 1.7 gldl in Step 1 and then to 8.0

* 0.4 gldl in Step 2. The results demonstrate that a

rise in free hemoglobin concentration correlated well with a rise in mean arterial pressure.

Results and Comparisons in Prior Investigations for Mean Arterial Pressure
The mean arterial pressure obtained through hemodilution with Hespan and
Oxyglobin are consistent with the results of previous studies. A number of studies have
described a decrease in mean arterial pressure during isovolemic hemodilution with a
non-oxygen-carrying plasma expander, apparently due to the consequential decrease in

blood viscosity (Krieter, Hagen et al. 1997; Tsai, Friesenecker et al. 1998; Tsai and
Intaglietta 2001). The pressor effect of hemoglobin-based oxygen carriers is also well
documented. There are primarily two competing theories as to the mechanism of the
hypertensive effect of HBOCs, either that nitric oxide (NO) scavenging occurs in the
vessel lumen andlor in the extravascular space or that there is excessive 0 2 delivery. The
former is the most widely accepted interpretation. Several studies describe in detail the
mechanism by which extracellular oxy-hemoglobin (Hb02) reacts at a high rate with NO
in the vessel lumen. Extravasation of Hb02 into the blood vessel wall also causes a
reaction to occur with NO in the extravascular space, thereby hampering normal NO
signaling that occurs between the endothelium and the smooth muscle (Shen, Hintze et al.
1995; Sarti, Giuffre et al. 2003; Olson, Foley et al. 2004).

Effects of Hemodilution with Hespan and Oxyglobin on Capillary PO2
Summary of Experimental Results for Red Blood Cell PO2
Hemodilution with Hespan resulted in a linear decrease in RBC PO2 as the
hematocrit was systematically decreased through the two hemodilution steps (see Figure
17). Hemodilution with Oxyglobin caused a similar linear decrease in RBC PO2. A
statistically significant difference was found when comparing the two linear regressions
using a Bivariate Linear Fit Model with subsequent Analysis of Variance indicating that
Hespan over the entire course of hemodilution was able to maintain RBC PO2 better than

Oxyglobin. The linearity of both Hespan and Oxyglobin data suggest that RBC PO2 is
dependent on hematocrit.
Hemodilution with Hespan resulted in the expected decrease in total hemoglobin
concentration and concurrent decrease in RBC PO2to 22.2

* 10.6 mmHg. Using

Oxyglobin as the hemodiluent the total hemoglobin concentration was kept above 11
gldl, but the RBC PO2 sustained a much steeper decline with a POz of 11.6

* 11.0 mmHg

in Step 2.
Plasma hemoglobin concentrations increased from 5.2

* 1.5 gldl (Step 1) and then

* 0.4 gldl as expected, contributing significantly to the total hemoglobin
concentrations of 13.1 k 0.4 gldl (Step 1) and 11.3 * 0.5 gldl (Step 2). RBC PO2, despite

to 8.0

the contribution of free hemoglobin to the plasma, did not benefit from its increased
oxygen carrying capacity.
RBC PO2 decreases in capillaries amid the decrease in systemic hematocrit and
hemoglobin concentrations because there are fewer red blood cells to deliver oxygen and
maintain tissue consumption levels. Therefore, more oxygen off loading occurs in
arterioles before the red blood cells reach the capillaries resulting in the low RBC P02.
This process might be facilitated by the addition of cell-free hemoglobin.
Overall, all RBC PO2 values for the hemodilution Steps 1 and 2 for Oxyglobin
and Hespan were determined to be statistically significant from Control values using a
One Way Analysis of Variance. Tukey's Multiple Comparisons test revealed that all
other values are significant when compared to each other except Step 1 values.

Summary of Experimental Results for Plasma Gap PO2
Hemodilution with Hespan resulted in a linear decrease in PG PO2 as hematocrit
was systematically decreased through the hemodilution steps. Hemodilution with
Oxyglobin caused a similar linear decrease in PG PO2. Although the linear correlation
for the Hespan values is 0.971 it is not statistically significant (p = 0.15). Linear
regression statistics indicate a similarly high linear correlation for Control and Oxyglobin
Steps 1 and 2 (R = 0.999) that is statistically significant (p = 0.027). When comparing
the linear regressions using a Bivariate Linear Fit Model with subsequent Analysis of
Variance, a significant difference was revealed indicating that Hespan, over the entire
course of hemodilution, yielded a higher PG POz than Oxyglobin. The high linear
correlation of both Hespan and Oxyglobin data indicates that most of the variation of PG
PO2 can be accounted for the hematocrit.
PG PO2 versus total hemoglobin concentration and plasma hemoglobin closely
parallel those of the RBC PO2 plots. One note of interest is that PG PO2 was 32.8
mmHg (Step 1) and 11.6

* 11.0 mmHg (Step 2) when using Oxyglobin as the

hemodiluent. Using Hespan as the hemodiluent resulted in PG PO2 values of 35.2
mmHg (Step 1) and 20.9

* 10.0

* 18.0

* 10.3 mmHg (Step 2).

One Way Analysis of Variance determined that the PG PO2 values of
hemodilution Steps 1 and 2 for Oxyglobin and Hespan are statistically significant
compared to Control values. Tukey's Multiple Comparisons test revealed that the Step 1
values for Oxyglobin and Hespan are not significantly different, while there is a
significant difference between Oxyglobin Step 2 and Hespan Step 2. PG PO2 was

expected to be higher for the Oxyglobin groups considering the contribution of cell-free
hemoglobin in the plasma.

Summary of Experimental Results for APOz
As hematocrit was systematically reduced during hemodilution using Hespan and
Oxyglobin, AP02 was dramatically reduced after Step 1. APO2 for Steps 1 and 2 of the
hemodilution protocol with Hespan were approximately the same (1.6 i 5.4 mmHg and
1.3 f 2.0 mmHg, respectively), while AP02 for Steps 1 and 2 using Oxyglobin as the
hemodiluent varied slightly (1.6 i 2.6 mmHg and 0.0

* 1.1 mmHg, respectively).

When considering the dependence of AP02 on total hemoglobin concentration,
there was approximately an 8 mmHg change in APOz going from a total hemoglobin
concentration of 13.5 i 0.6 gldl (Control) to 10.8 f 4.7 gldl (Step I), when using Hespan
as the hemodiluent. This was only a small and non-significant change in AP02 between
hemodilution Steps 1 and 2 using Hespan. Using Oxyglobin as the hemodilution fluid,

*

total hemoglobin concentration varied only slightly, decreasing from 13.5 0.6 gldl
(Control) to 11.3 f 0.5 gldl (Step 2), and AP02 decreased to 0.0

* 1.1 mmHg.

Consideration of the plasma hemoglobin concentration provides additional insight
into the variation of AP02 with total hemoglobin concentration. Hemodilution with
Oxyglobin adds extracellular hemoglobin molecules which causes total hemoglobin
concentration to remain stable during hemodilution. As more cell-free hemoglobin was
added to the plasma from 0 gldl (Control) to 5.3 i 1.5 gldl (Step 1) and then to 8.0

* 0.4

gldl (Step 2), the difference in POz between RBCs and plasma gaps virtually disappeared,
as expected.
Student's t-tests determined that significant differences exist between plasma gap
PO2 and red blood cell POz (AP02) in the following: 1) Control group (p<0.0001) with a
AP02 of 9.7 k 9.1 mmHg; 2) Oxyglobin hemodilution Step 1 (p<0.05) with a APOz of 1.6
k 2.6 mmHg; 3) Hespan hemodilution Step 2 (p<0.0001) with a APOz of 1.3 k 2.0

mmHg.

Interpretation of Results and Comparison with Prior Investigations
The components of total hemoglobin concentration of the blood, namely the
concentration of hemoglobin contained within RBCs and that contained in the plasma
were calculated from the following equation:

where [HbITotalis the total hemoglobin concentration in the blood, [HbIRBCis the
hemoglobin concentration of a single RBC, Hf is the final hematocrit, and [Hb],laSmais the
hemoglobin concentration in the plasma.
Hemodilution with Hespan caused almost a three-fold reduction in total
hemoglobin concentration, dropping below the transfusion trigger for packed red blood
cells normally recognized at 7 gldl (Intaglietta 1999; Tsai and Intaglietta 2001) after Step
2 ([Hb]plas,a= 5.1 k 0.8 gldl). This explains the significant decrease in RBC and mean

capillary POz (Table 4). The addition of extracellular hemoglobin molecules in the form
of Oxyglobin increased plasma hemoglobin concentration, keeping total hemoglobin
concentration close to the Control value. Although total hemoglobin concentration was
stabilized by the addition of cell-free hemoglobin, it did not improve the overall delivery
of oxygen to the capillaries as evident in the mean capillary PO2. Equalization of PO2
between the RBCs and plasma gaps was observed after the final hemodilution step with
Oxyglobin resulting in a AP02 of practically 0 mmHg. Although this result was
expected, if not so dramatically, Oxyglobin did not have a stabilizing effect on mean
capillary PO2; rather, it caused a decrease to approximately one-half of the Hespan Step 2
capillary PO2 value. Prior investigations in our laboratory using measurements taken at
the arteriolar and venular ends of capillaries to determine capillary PO2 (Miller 2000; Tait
2000), have shown that capillary PO2 decreases with systematic reduction of hematocrit
when using Hespan as a hemodiluent. However, when using different HBOCs as the
hemodiluent, mean capillary PO2 remained at stable levels throughout the systematic
reduction in hematocrit. This led to the conclusion that total hemoglobin concentration is
a major determinant of capillary PO2. This is contrary to the results obtained with
Oxyglobin in this study.
Although MAP increased and total hemoglobin concentration was well
maintained with the addition of Oxyglobin, PO2 in the capillaries was dramatically
reduced. Oxygen-carrying plasma expanders should reduce intracapillary resistance,
facilitating oxygen offloading into nearby tissue, and should also increase the oxygen
carrying capacity in the blood maintaining near to normal values as mentioned above.

Tsai (Tsai 2001) reported abnormally low tissue oxygenation and functional capillary
density (FCD), a measurement of the number of red blood cell perfused capillaries as a
measure of oxygen supply, with Oxyglobin during low hemoglobin content conditions
(<50%). Perhaps this can help to explain the abnormally low mean capillary PO2
observed in this case.
Another facet to the explanation of abnormally low mean capillary PO2 that is
seen with this particular HBOC might be due to NO scavenging. Evidence from multiple
studies demonstrate that NO reversibly inhibits cytochrome c oxidase, the terminal
enzyme of the mitochondrial respiratory chain (Brown and Cooper 1994; Cleeter, Cooper
et al. 1994; Schweizer and Richter 1994; Sarti, Giuffre et al. 2003). In fact, nanomolar
concentrations of NO cause the inhibition of cytochrome c oxidase which inhibits normal
mitochondrial function causing oxygen consumption to decrease (Brown and Cooper
1994). One particular study found that the inhibition of NO synthesis with nitro-Larginine (NLA, lo4 moVL) caused the opposite to occur, consumption of oxygen
increased in the tissue by 55*9% (Shen, Hintze et al. 1995).
Putting this into the context of hemodilution with a HBOC, NO scavenging that
occurs intravascularly in combination with HBOC extravasation into the interstitial space
between the vascular endothelium and smooth muscle could potentially scavenge enough
NO to mimic the effects of NLA. Considering this facet of NO activity along with
reduced FCD and vasoconstriction, capillaries observed in the current study may have
uniquely experienced a drastic reduction of oxygen supply and a concurrent increase in

demand resulting in very low mean capillary PO2 at a reduced hematocrit when using
Oxyglobin as the hemodilution fluid.
The present study is the first to combine a hemodilution procedure with EAT
measurements in skeletal muscle. A prior investigation from this laboratory determined
PO2 in single capillaries, taking into account heterogeneity in PO2, indicating the
presence of PO2 gradients within the plasma (Zheng, Golub et al. 1996). More recent
experimental data from this laboratory, using the rat mesentery, concluded the existence
and measurability of PO2 gradients within the plasma gaps between RBCs (Golub and
Pittman 2005). The present study has made the determination that the magnitude of the
EATs depends on the capillary PO2 values. Table 4 shows the general trend of a
corresponding decrease in capillary PO2 and AP02 for the one second observation period.
Golub and Pittman (2005) found that EATs in mesenteric capillaries were less prominent
in capillaries with high average PO2 and more prominent in capillaries with low P02.
Results from this study found that the largest AP02 with statistical significance occurred
in the Control group, which had the highest capillary PO2. Other statistically significant
differences in AP02 were revealed in Oxyglobin Step 1 and Hespan Step 2. Though
statistically significant, the latter condition was hypothesized to have the largest AP02
because of an expected increase in spacing between RBCs when hematocrit is reduced
which in turn increasing intracapillary resistance to oxygen delivery resulting in an
increase in EAT transients.
For normal cell separation distance (about 10 pm) and oxygen content of RBCs,
the magnitudes of EATs in capillaries of resting tissue have predicted values of 10 mmHg

(Wang and Popel 1993; Kisliakov 1996), consistent with the Control AP02 from this
investigation. Another study calculated oxygen PO2 gradients in peripheral capillaries
(Lawson and Forster 1967). Calculating the PO2 difference between red cells and plasma
under numerous conditions, they hypothesized that under normal resting conditions APOz
should be 0.2 mmHg and under anemic conditions ([Hb]~otal=3.7 gldl) AP02 should be
1.1 mmHg. These calculations were not completely congruent with the data collected in
this study. Under Control conditions (considered normal resting) AP02 was highest at

* 9.1 mmHg and under similar anemic conditions ([HbITot,,= 5.1 * 0.8 gldl, Hespan
Step 2) AP02 1.3 * 2.0 mmHg. Many other mathematical calculations have predicted a

9.7

much higher AP02 than what has been observed either by this study or by Golub and
Pittman (Homer, Weathersby et al. 198 1; Wang and Pope1 1993; Golub and Pittman
2005).
Finally, it was suggested by Golub and Pittman (2005) that intracapillary
resistance would decrease with the addition of an oxygen-carrying blood substitute,
thereby damping the modulation of EATS. This is consistent with the present study
which found no statistical significance in AP02 for hemodilution Step 2 with Oxyglobin,
where the final hematocrit was one-third what it was initially and total hemoglobin
deviated only slightly from the Control value.

Summary and Conclusion
Hemodilution with Oxyglobin resulted in a significant increase in mean arterial
pressure as hematocrit was reduced and resulted in a significant contribution to total

hemoglobin concentration. Conversely, hemodilution with Hespan did not significantly
alter mean arterial pressure and resulted in a dramatic decrease in total hemoglobin
concentration, below the transfusion trigger after Step 2.
Considering EATS, it was determined that the magnitude of EAT modulation
decreased with decreased capillary PO2. Furthermore, it was determined that the
magnitude of EAT modulation was related to hematocrit and hemoglobin concentration
and that these varied depending on the hemodiluent used. With the systematic reduction
of hematocrit, both hemodiluents caused a rapid decline in RBC and PG PO2. At the
hemodilution levels used in this study, Hespan demonstrated the ability to maintain PO2
at higher levels when compared to Oxyglobin. Although Oxyglobin maintained total
hemoglobin concentration near normal, with a significant contribution to the plasma
hemoglobin concentration, it did not increase the oxygen delivery of blood in the
capillaries but did cause EAT modulation to minimize, reducing the PO2 gradient
between the plasma and red blood cells. Hespan had no effect on hemoglobin
concentration.
AP02 was determined to be statistically significant in three of the five
experimental conditions including Control, Oxyglobin Step 1, and Hespan Step 2. The
largest numerical AP02 occurred under Control conditions. Furthermore, the addition of
Oxyglobin increased plasma hemoglobin concentration, keeping total hemoglobin
concentration well above the "transfusion trigger", while causing the virtual abolishment
of a PO2 gradient between RBCs and plasma gaps. In conclusion, using PQM and the

previous experimental parameters of Golub and Pittrnan (2005), EATs in capillary PO2
have been observed experimentally in the rat spinotrapezius muscle.

Recommendations for Future Studies
Parameters used in mathematical models, such as lineal density of RBCs, RBC
spacing, RBC velocity, and RBC shape (Federspiel and Sarelius 1984; Federspiel and
Pope1 1986; Groebe and Thews 1989; Tsai and Intaglietta 1989; Wang and Pope1 1993),
should be experimentally measured to help answer questions concerning inter-RBC PO2
resistance, oxygen flux at the capillary wall, and tissue PO2 oscillations associated with
PO2 gradients between red blood cells and plasma gaps. A proposed technique to allow
the determination of the values mentioned above would be the simultaneous
measurement of EATs and video images of red blood cells and plasma gaps. With the
dual acquisition of PO2 and spatial data, the relationship between PO2 and other variables
such as RBC and capillary geometry and RBC flow dynamics could be compared with
predictions of mathematical models.
Measurement of EATs in contracting skeletal muscle, where there is increased
blood flow (with shorter residence time for RBCs in capillaries) and higher oxygen
consumption, would be of interest to study the effects of the discrete nature of blood flow
on oxygen transport to tissue via capillaries. A previous mathematical model (Groebe
and Thews 1989), considered the impact of increased inter-erythrocyte plasma gap
spacing and concluded that plasma gap spacing does not play an important role for tissue
oxygen supply as long as overall capillary oxygen flux stays constant. Perhaps,

examining EATs under exercise conditions with increased red blood cell flux in
capillaries and capillary recruitment can shed some light on this and similar issues. The
effects of Oxyglobin and other hemoglobin-based oxygen carriers on EATs and capillary
PO2 under these conditions might also be considered.
Another proposal related to the present study would be the determination of
functional capillary density following administration of Oxyglobin. Various studies have
reported conflicting conclusions regarding the ability of hemoglobin-based oxygen
carriers to maintain or decrease functional capillary density (Tsai, Friesenecker et al.
1995; Tsai 2001) with one study involving the use of Oxyglobin. Furthermore, FCD
determination after the administration of an HBOC in conjunction with a vasodilator
might also be of interest.
Finally, future study involving the comparison of Oxyglobin to the human HBOC
@HBOC,
product from Biopure would be worthwhile. The human product ~ e m o ~ u r eor
201, is a bovine hemoglobin glutamer - 250. As a result of its increased size (32 to 500

kD compared to Oxyglobin molecular weight between 65 and 130 kD with no more than
10% having a molecular weight >500 kD) and improved purification, different results
may be observed.
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